FDA Clearance Tracker · P050020
FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITOR
Last checked: Nov 20, 2026Latest source record: Mar 12, 2008 (this decision)Source: openFDAMethods & limitations
Decided
Mar 12, 2008
Approval withdrawn
Time to decision
1,008 days
Received Jun 8, 2005. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P050020
- Device name
- FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITOR
- Applicant
- Abbott Laboratories
- Applicant location
- Alameda, CA
- Received
- Jun 8, 2005
- Decided
- Mar 12, 2008
- Decision
- Approval withdrawn
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 30 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Sensor, glucose, invasive (MDS)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITORING SYSTEM. THE DEVICE IS INDICATED FOR THE FOLLOWING: THE FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITORING SYSTEM IS INDICATED FOR CONTINUALLY RECORDING INTERSTITIAL FLUID GLUCOSE LEVELS IN PEOPLE (AGES 18 AND OLDER) WITH DIABETES MELLITUS FOR THE PURPOSE OF IMPROVING DIABETES MANAGEMENT. READINGS AND ALARMS ABOUT GLUCOSE LEVELS FROM THE FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITORING SYSTEM ARE NOT INTENDED TO REPLACE TRADITIONAL BLOOD GLUCOSE MONITORING. BEFORE ADJUSTING THERAPY FOR DIABETES MANAGEMENT BASED ON THE RESULTS AND ALARMS FROM THE FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITORING SYSTEM, TRADITIONAL BLOOD GLUCOSE TESTS MUST BE PERFORMED. THE FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITORING SYSTEM PROVIDES A BUILT-IN BLOOD GLUCOSE METER TO CONFIRM THE CONTINUOUS GLUCOSE RESULT. THE FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITORING SYSTEM PROVIDES REAL-TIME READINGS, GRAPHS, TRENDS AND GLUCOSE ALARMS DIRECTLY TO THE USER. THE FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITORING SYSTEM IS INTENDED TO BE USED IN HOME SETTINGS TO AID PEOPLE WITH DIABETES IN PREDICTING AND DETECTING EPISODES OF HYPOGLYCEMIA AND HYPERGLYCEMIA AND IN CLINICAL SETTINGS TO AID HEALTHCARE PROFESSIONALS IN EVALUATING GLUCOSE CONTROL. THE FREESTYLE NAVIGATOR CONTINUOUS GLUCOSE MONITORING SYSTEM IS AVAILABLE ONLY BY PRESCRIPTION.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MDS. The earliest in FDA's data is P980022, decided Jun 15, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.